Summary: A new study shows that coating neural prosthetic implants with the anti-inflammatory drug dexamethasone helps reduce the body’s immune response and scar tissue formation. This strategy enhances the long-term performance and stability of electrodes used to connect prosthetic limbs to the nervous system.
Researchers chemically modified the surface of polyimide electrodes to enable a slow release of the drug at the implant site over two months. Animal testing confirmed the method significantly reduced inflammation while preserving biocompatibility, offering a breakthrough for chronic neuroprosthetic use.
Key Facts:
- Drug Coating Innovation: Dexamethasone was covalently bound to the electrode surface for sustained local release.
- Reduced Immune Reaction: The coating lowered inflammation and scar tissue in preclinical models.
- Improved Stability: Implants maintained biocompatibility and mechanical function over critical early months.
Source: UAB
An international research team, including scientists from the Institut de Neurociències at the Universitat Autònoma de Barcelona (UAB), has developed a new solution to reduce the immune response triggered by neural prosthetics used after limb amputations or severe nerve injuries.
The approach consists of coating the electronic implants (which connect the prosthetic device to the patient’s nervous system) with a potent anti-inflammatory drug. This coating helps the body better tolerate the implant, improving its long-term performance and stability.
Neural electrode implants are commonly used in prosthetics to restore communication between the device and the nervous system.
However, their long-term effectiveness can be compromised by the body’s natural immune reaction to foreign objects, which leads to the formation of scar tissue around the implant and can impair its function.
Now, a recent study published in Advanced Healthcare Materials by researchers from the Universitat Autònoma de Barcelona, the Università di Ferrara, the University of Freiburg, and Chalmers University of Technology, conducted as part of the European collaborative project BioFINE, reports a novel method to improve the biocompatibility and chronic stability of these electrodes.
The technique involves activating and modifying the surface of polyimide (a material commonly used for implanted electrodes) using a chemical strategy that enables the covalent binding of the anti-inflammatory drug dexamethasone.
This innovation allows the drug to be released at the implant site slowly over at least two months, a critical period when the immune system typically mounts its strongest response.
Biological tests showed that this approach reduces inflammation-related signals in immune cells, while maintaining the material’s biocompatibility and mechanical integrity.
Animal testing further confirmed that the dexamethasone-releasing implants significantly reduce immune reactions and scar tissue formation around the device.
These findings suggest that the slow and localized release of dexamethasone from the implant surface could extend the functional lifespan of neural prostheses, offering a promising step forward in addressing the long-term challenges of implantable neurotechnology.
“This is a main step that has to be complemented by the demonstration in vivo that this coating improves the functional performance of chronically implanted electrodes in the peripheral nerves, for stimulating and recording nerve signals”, says Dr. Xavier Navarro, principal investigator of the UAB team in the BioFINE project.
About this neuroscience and neurotech research news
Author: Octavi Lopez
Source: UAB
Contact: Octavi Lopez – UAB
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Covalent Binding of Dexamethasone to Polyimide Improves Biocompatibility of Neural Implantable Devices” by Xavier Navarro et al. Advanced Healthcare Materials
Abstract
Covalent Binding of Dexamethasone to Polyimide Improves Biocompatibility of Neural Implantable Devices
Neural implants are widely used in prosthetic applications to interact with the peripheral nervous system, but their long-term functionality is compromised by foreign body reactions (FBR).
Thanks to its high biocompatibility, polyimide poly (biphenyl dianhydride)-p-phenylenediamine (BPDA-PDA) represents a suitable material to fabricate ultrathin and ultra-flexible neural implants.
This study explores the surface functionalization of BPDA-PDA, the electrically inert component of the neural implant.
The novelty of this approach relies on the fact that dexamethasone (DEX covalently bound to BPDA-PDA, enabling its sustained release over a period of at least 9 weeks.
In vitro assays demonstrate that this strategy reduce the production of pro-inflammatory markers in macrophages.
In addition, the biocompatibility of the functionalized material has been ensured by evaluating the viability of dorsal root ganglia (DRG) neurons.
Furthermore, in vivo implantation of DEX functionalized BPDA-PDA substrates shows a significant reduction in inflammatory cell infiltration and fibrotic capsule thickness formed around the devices.
These findings suggest that local release of DEX from the electrically inactive scaffold of neural implants may enhance their long-term stability and performance by mitigating the FBR.
